SCHEMBL3608320

SCHEMBL3608320

CCOC(=O)c1cncc(-c2nnc(N3CCC(O)CC3)s2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HRH3 Q9Y5N1 9/20 0.43
PDE5A O76074 1/20 0.43
DPP4 P27487 1/20 0.41
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
CPT2 P23786 1/20 0.40
CPT1A P50416 1/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ATM Q13315 1/20 0.39
P2RY12 Q9H244 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3611636 0.87 SCD (0.45) HRH3PDE5ADPP4DPP8DPP9
SCHEMBL3611311 0.78 SCD (0.49) CYP2C9CYP2C19HRH3PDE5ADPP4
SCHEMBL3601603 0.77 SCD (0.54) CYP2C9CYP2C19HRH3PDE5ADPP4
SCHEMBL3603342 0.76 OPRK1 (0.51) CYP2C9CYP2C19DPP4DPP8DPP9
SCHEMBL3603338 0.76 SCD (0.51) CYP2C9CYP2C19HRH3PDE5ADPP4
SCHEMBL4211279 0.72 OGA (0.49) HRH3PDE5ATDP1P2RY12
SCHEMBL13779214 0.72 CYP2C19 (0.52) CYP2C9CYP2C19NPC1ALDH1A1SMN1; SMN2
SCHEMBL3607341 0.69 CYP2C9 (0.47) CYP2C9CYP2C19DPP4DPP8DPP9
SCHEMBL20188020 0.68 CYP2C19 (0.60) CYP2C9CYP2C19DPP4DPP8DPP9
SCHEMBL277284 0.68 CYP2C19 (0.86) CYP2C9CYP2C19ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004245-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-01-07 US disclosed
EP-2076509-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Frosst Canada Ltd. (CA) 2009-07-08 EP disclosed
WO-2008046226-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004245-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, SREBF1 CYP2C9 592/4885CYP2C19 1227/4885HRH3 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.